NASDAQ : PBLS
Parabilis Medicines, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 28.32 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.50B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.45B |
| Enterprise Value | 2.38B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 121.95M |
| Shares Outstanding | 123.53M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +816.33% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 53.90% |
| Float | 82.07M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 23,638.25 |
| Forward PS | 846.40 |
| PB Ratio | 3.34 |
| P/TBV Ratio | 3.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 16,387.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 17.91 |
| Quick Ratio | 17.83 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -139.58 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -15.42% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $1,021 |
| Profits Per Employee | -$1.60M |
| Employee Count | 145 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 32.96 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 48.49 |
| Average Volume (20 Days) | 1,203,574 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.25M |
| Short Previous Month | 8.26M |
| Short % of Shares Out | 7.49% |
| Short % of Float | 11.27% |
| Short Ratio (days to cover) | 7.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 148,000 |
| Gross Profit | -12.95M |
| Operating Income | -171.54M |
| Pretax Income | -170.53M |
| Net Income | -231.67M |
| EBITDA | -169.11M |
| EBIT | -171.54M |
| Loss Per Share | -$23.45 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.12B |
| Total Debt | 47.51M |
| Net Cash | 1.07B |
| Net Cash Per Share | $8.69 |
| Equity (Book Value) | 1.05B |
| Book Value Per Share | 8.48 |
| Working Capital | 1.06B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -111.29M |
| Capital Expenditures | -1.20M |
| Depreciation & Amortization | 2.43M |
| Net Borrowing | -10.61M |
| Free Cash Flow | -112.49M |
| FCF Per Share | -$0.91 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -115,907.43% |
| Pretax Margin | -115,224.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -83.88% |
| FCF Yield | -3.22% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $41.40 |
| Price Target Difference | 48.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 16.24 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |